Back to Authors

Sylvester, Richard

https://orcid.org/0000-0003-0529-862X

Mayo Clinic

European Organisation for Research and Treatment of Cancer

Citations 2

The impact of re‐transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high‐grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin
Sylvester, Richard , Joniau, Steven , Oderda, Marco , Serretta, Vincenzo , Larré, S. , Stasi, Savino M. Di , Rhijn, Bas van, Witjes, Alfred, Grotenhuis, Anne J., Colombo, Renzo , Briganti, Alberto , Babjuk, Marek , Soukup, Viktor , Malats, Núria , Baniel, Jack, Cai, Tommaso , Cha, Eugene K., Ardelt, Peter, Vakarakis, John, Bartoletti, Riccardo , Dalbagni, Guido , Xylinas, Évanguelos , Karnes, R. Jeffrey , Palou, Joan, Karnes, Robert J, Gontero, Paolo , Pisano, Francesca , Malmström, Per‐Uno , Irani, Jacques , Mano, Roy , Cha, Eugene K., Shariat, Shahrokh F. , Malats, Nuria , Joniau, Steven , Oderda, Marco

BJU International | October 15, 2015 | Volume: 118 | Issue: 1 | Pages: 44-52

10.1111/bju.13354 Get It

Objectives To determine if a re‐transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1‐high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1‐HG/G3 initially treated with bacille Calmette–Guérin, 935 (38%) had a re‐TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re‐TUR), group 2 (no muscle, re‐TUR), group 3 (muscle, no re‐TUR) and group 4 (muscle, re‐TUR). Clinical outcomes were compared across the four groups. Results Re‐TUR had a positive impact on recurrence, progression, CSS and OS only if muscle was not present in the primary TUR specimen. Adjusting for the most important prognostic factors, re‐TUR in the absence of muscle had a borderline significant effect on time to recurrence [hazard ratio (HR) 0.67, P = 0.08], progression (HR 0.46, P = 0.06), CSS (HR 0.31, P = 0.07) and OS (HR 0.48, P = 0.05). Re‐TUR in the presence of muscle in the primary TUR specimen did not improve the outcome for any of the endpoints. Conclusions Our retrospective analysis suggests that re‐TUR may not be necessary in patients with T1‐HG/G3, if muscle is present in the specimen of the primary TUR.
Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials
Sylvester, Richard , Meijden, Adrian P.M. van der, Lamm, Donald L.

Journal of Urology | January 18, 2006 | Volume: 168 | Issue: 5 | Pages: 1964-1970

10.1016/s0022-5347(05)64273-5 Get It